Gene therapy in the cardiovascular system: An update

Cardiovascular Research

Volumn 44, Issue 3, 1999, Pages 498-506

  Sinnaeve, Peter ^a,b   Varenne, Olivier ^a,c   Collen, Désiré ^a   Janssens, Stefan ^a,b,c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c BICHAT HOSPITAL   (France)

Author keywords

Atherosclerosis; Gene therapy; Heart failure; Hypertension; Infection inflammation; Thrombosis embolism

Indexed keywords

DNA; FIBRINOGEN RECEPTOR ANTAGONIST; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; EMBOLISM; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR DISEASES; CORONARY DISEASE; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; LYMPHOKINES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; SUPEROXIDE DISMUTASE; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033408536     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00259-X     Document Type: Review

References (125)

1. Levi M, Coronel R. Gene therapy in the cardiovascular system. Cardiovasc Res 1997;35:389-390.
2. DeYoung MB, Dichek DA. Gene therapy for restenosis: are we ready? Circ Res 1998;82:306-313.
3. Teirstein PS, Massullo V, Jani S et al. Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis. Circulation 1999;99:243-247.
4. Lewis BS, Flugelman MY, Weisz A, Keren-Tal I, Schaper W. Angiogenesis by gene therapy: a new horizon for myocardial revascularization? Cardiovasc Res 1997;35:490-497.
5. Melillo G, Scoccianti M, Kovesdi I et al. Gene therapy for collateral vessel development. Cardiovasc Res 1997;35:480-489.
6. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
7. Losordo DW, Vale PR, Symes JF et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
8. Henry TD, Annex BH, Azrin MA et al. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor. The VIVA Trial [abstract]. J Am Coll Cardiol 1999;33:384A.
9. Kornowski R, Fuchs S, Vodovotz Y et al. Successful gene transfer in a porcine ischemia model using the Biosense(tm) guided transendocardial injection catheter [abstract]. J Am Coll Cardiol 1999;33:355A.
10. Verrier RL, Waxman S, Lovett EG, Moreno R. Transatrial access to the normal pericardial space: a novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Circulation 1998;98:2331-2333.
11. March KL, Woody M, Mehdi K et al. Efficient in vivo catheter-Clinbased pericardial gene transfer mediated by adenoviral vectors. Clin Cardiol 1999;22:I23-I29.
12. Macris MP, Igo SR. Minimally invasive access of the normal pericardium: initial clinical experience with a novel device. Clin Cardiol 1999;22:I36-I39.
13. Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363.
14. Aoki M, Morishita R, Matsushita H et al. Beneficial angiogenesis induced by over-expression of human hepatocyte growth factor (HGF) in non-infarcted and infarcted myocardium: potential gene therapy for myocardial infarction [abstract]. Circulation 1998;98:I321.
15. Bouloumie A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998;83:1059-1066.
16. Brizzi MF, Battaglia E, Montrucchio G et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 1999;84:785-786.
17. Shyu K, Vincent KA, Magner M et al. Naked DNA encoding an hypoxia-inducible factor 1α (HIF-1α)/VP16 hybrid transcription factor enhances angiogenesis in rabbit hindlimb ischemia: an alternate method for therapeutic angiogenesis utilizing a transcriptional regulatory system [abstract]. Circulation 1998;98:I68.
18. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998;101:2567-2578.
19. Babaei S, Teichert-Kuliszewska K, Monge JC et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998;82:1007-1015.
20. de Boer OJ, van der Waal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999;41:443-449.
21. Inoue M, Itoh H, Ueda M et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-2116.
22. Moulton KS, Heller E, Konerding MA et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimai neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-1732.
23. Staab ME, Simari RD, Srivatsa SS et al. Enhanced angiogenesis and unfavorable remodeling in injured porcine coronary artery lesions: effects of local basic fibroblast growth factor delivery. Angiology 1997;48:753-760.
24. Aiello LP, Avery RL, Arigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
25. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
26. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-1236.
27. Van Belle E, Tio RA, Chen D et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimai thickening. J Am Coll Cardiol 1997;29:1371-1379.
28. Hartikainen J, Eranen J, Laitinen M et al. Intracoronary gene transfer after angioplasty. Short term follow-up of patients in phase I Kuopio angioplasty gene transfer trial (KAT Trial) [abstract]. Circulation 1998;98:I352.
29. Kutryk MJB, Serruys PW, Bruining N et al. Randomized trial of antisense oligonucleotide against c-myc for the prevention of restenosis after stenting: results of the Thoraxcenter 'ITALICS' trial [abstract]. Eur Heart J 1998;19(Suppl):569.
30. Shi Y, Fard A, Galeo A et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994;90:944-951.
31. Baek S, March KL. Gene therapy for restenosis: getting nearer the heart of the matter. Circ Res 1998;82:295-305.
32. Braun Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-89.
33. Varenne O, Pislaru S, Gillijns H et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998;98:919-926.
34. Duckers H, Park JL, San HB et al. Protective properties of recombinant heme oxygenase 1 in vitro and in vivo in the balloon injured porcine artery [abstract]. Circulation 1998;98:I739.
35. Ueno H, Haruno A, Morisaki N et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 1997;96:2272-2279.
36. Schneider DB, Sassani AB, Vassalli G, Driscoll RM, Dichek DA. Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors. J Vase Surg 1999;29:543-550.
37. Gonschior P, Goetz AE, Huehns TY, Hofling B. A new catheter for prolonged local drug application. Coron Artery Dis 1995;6:329-334.
38. Feldman LJ, Steg G. Optimal techniques for arterial gene transfer. Cardiovasc Res 1997;35:391-404.
39. Varenne O, Gerard R, Sinnaeve P et al. Percutaneous adenoviral gene transfer into porcine coronary arteries: is catheter-based gene delivery adapted to coronary circulation? Hum Gene Ther 1999;10:1105-1115.
40. Rekhter MD, Simari RD, Work CW et al. Gene transfer into normal and atherosclerotic human blood vessels. Circ Res 1998;82:1243-1252.
41. Steg PG, Tahlil O, Aubailly N et al. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997;96:408-411.
42. Lafont A, Durand E, Vilde F et al. Thrombus generation after adenovirus-mediated gene transfer into atherosclerotic arteries. Hum Gene Ther 1998;9:2795-2800.
43. Wever RM, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998;97:108-112.
44. 2-production in the pig coronary artery. Circulation 1997;96:3593-3601.
45. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 1999;99:2979-2982.
46. Le Tourneau T, Van Belle E, Corseaux D et al. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hy-percholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. J Am Coll Cardiol 1999;33:876-882.
47. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-1254.
48. Varenne O, Sinnaeve P, Gillijns H et al. Adenoviral mediated NOS3 gene transfer in porcine coronary arteries reduces in stent restenosis [abstract]. J Am Coll Cardiol 1999;33:59A.
49. Tio RA, Scheuermann TH, Lebherz C et al. Adenovirus-mediated GAX gene transfer reduces in-stent restenosis in pig coronary arteries [abstract]. Circulation 1998;98:I675.
50. Frimerman A, Welch PJ, Jin X et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999;99:697-703.
51. Klugherz BD, Chen W, Jones P et al. Successful gene transfer to the arterial wall using a DNA-eluting polymer-coated intracoronary stent in swine [abstract]. J Am Coll Cardiol 1999;33:60A.
52. Ye YW, Landau C, Meidell RS et al. Improved bioresorbable microporous intravascular stents for gene therapy. ASAIO J 1996;42:M823-M827.
53. Flugelman MY, Dichek DA. Seeding of intracoronary stents with endothelial cells: current status and future prospects. J Interv Cardiol 1995;8:383-385.
54. Mann MJ, Gibbons GH, Hutchinson H et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci USA 1999;96:6411-6416.
55. Baker AH, Mehta D, George SJ, Angelini GD. Prevention of vein graft failure: potential applications for gene therapy. Cardiovasc Res 1997;35:442-450.
56. Mann MJ. E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts. Antisense Nucleic Acid Drug Dev 1998;8:171-176.
57. Mann MJ, Whittemore AD, Donaldson MC et al. The PREVENT Trial of vein graft genetic engineering: preliminary molecular and clinical findings [abstract]. Circulation 1998;98:I321.
58. Schwartz LN, Moawad J, Svensson EC et al. Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vase Surg 1999;29:874-881.
59. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998;5:1552-1560.
60. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998;9:867-877.
61. O'Blenes SB, Zaidi SHE, Rabinovitch M. Gene transfer with elafin reduces neointimal formation and promotes adventitial remodeling in vein grafts [abstract]. Circulation 1998;98:I319.
62. Bai H, Morishita R, Kida I et al. Inhibition of intimai hyperplasia after vein grafting by in vivo transfer of human senescent cellderived inhibitor-1 gene. Gene Ther 1998;5:761-769.
63. Suzuki J, Isobe M, Morishita R, Aoki M, Horie S, Okubo Y, Kaneda Y, Sawa Y, Matsuda H, Ogihara T, Sekiguchi M. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997;3:900-903.
64. Grossman M, Rader DJ, Muller DW et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-1154.
65. Fruchart JC, Duriez P. High density lipoproteins and coronary heart disease. Future prospects in gene therapy. Biochimie 1998;80:167-172.
66. Li J, Fang B, Eisensmith RC et al. In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995;95:768-773.
67. Kozarsky KF, Jooss K, Donahee M, Strauss JF, Wilson JM. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996;13:54-62.
68. Schlaepfer IR, Eckel RH. Plasma triglyceride reduction in mice after direct injections of muscle-specific lipoprotein lipase DNA. Diabetes 1999;48:223-227.
69. Gerard RD, Collen D. Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. Cardiovasc Res 1997;35:451-458.
70. Hasty AH, Linton MF, Brandt SJ et al. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 1999;99:2571-2576.
71. Benoit P, Emmanuel F, Caillaud JM et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999;99:105-110.
72. Morishita R, Yamada S, Yamamoto K et al. Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation 1998;98:1898-1904.
73. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999;41:402-417.
74. Schneider DB, Fly CA, Dichek DA, Geary RL. Adenoviral gene transfer in arteries of hypercholesterolemic nonhuman primates. Hum Gene Ther 1998;9:815-821.
75. Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci USA 1999;96:324-326.
76. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Guidelines for the evaluation and management of heart failure. Circulation 1995;92:2764-2784.
77. Laugwitz KL, Ungerer M, Schoeneberg T et al. Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes. Circulation 1999;99:1776-1779.
78. Hajjar RJ, Schmidt U, Matsui T et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998;95:5251-5256.
79. Maurice JP, Hata JA, Shah AS et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 1999;104:21-29.
80. Svensson EC, Marshall DJ, Woodard K et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999;99:201-205.
81. Li Q, Bolli R, Qiu Y et al. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 1998;98:1438-1448.
82. Woo YL, Zhang JC, Vijayasarathy C et al. Recombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischemic contractile dysfunction. Circulation 1998;98:II255-II260.
83. Morishita R, Sugimoto T, Aoki M et al. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-899.
84. Leor J, Quinones MJ, Patterson M, Kedes LK, Kloner RA. Adenovirus-mediated gene transfer into infarcted myocardium: feasibility, timing, and location of expression. J Mol Cell Cardiol 1996;28:2057-2067.
85. Leor J, Prentice H, Sartorelli V et al. Gene transfer and cell transplant: an experimental approach to repair a 'broken heart'. Cardiovasc Res 1997;35:431-441.
86. Lattanzi L, Salvatori G, Coletta M et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer: an alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 1998;101:2128.
87. Bowles NE, Wang Q, Towbin JA. Prospects for adenovirus-me-dialed gene therapy of inherited diseases of the myocardium. Cardiovasc Res 1997;35:422-430.
88. Wright MJ, Wightman LML, de Alwis M et al. Intracoronary and direct intramyocardial injection gene transfer to the in vivo rabbit heart: a comparison of viral and non-viral vectors [abstract]. Circulation 1998;98:I527.
89. Fromes Y, Salmon A, Wang X et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther 1999;6:683-688.
90. Boekstegers P, von Degenfeld G, Heinrich D, Steinbeck G, Katus H, Franz W. Regional and highly efficient myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins [abstract]. J Am Coll Cardiol 1999;33:233A.
91. Palma EC, Gallinghouse J, Ma T, Keung EC, Simpson PC, Long CS, Lee RJ. Adenoviral overexpression of SERCA2a prevents triggered activity induced by interleukin-1β in neeonatal rat myocytes [abstract]. Circulation 1998;98:I415.
92. Priori SG. Gene specific therapy for cardiac disease: the case of long QT syndrome. Rev Port Cardiol 1999;17(Suppl 3):III27-III38.
93. Brugada R, Brugada J, Roberts R. Genetics of cardiovascular disease with emphasis on atrial fibrillation. J Interv Cardiol Electrophysiol 1999;3:7-13.
94. Vassalli G, Dichek DA. Gene therapy for arterial thrombosis. Cardiovasc Res 1997;35:459-469.
95. Waugh JM, Kattash M, Li J et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 1999;96:1065-1070.
96. Waugh JM, Yuksel E, Li J et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 1999;84:84-92.
97. Nishida T, Ueno H, Atsuchi N et al. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res 1999;84:1446-1452.
98. Bates SM, Weitz JI. Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc Res 1999;41:418-432.
99. Gelband CH, Reeves PY, Dong H et al. Reversal of hypertension by retroviral-mediated (LNSV) delivery of angiotensin II type 1 receptor antisense (AT1R-AS) in the adult spontaneous hypertensive rat (SHR) [abstract]. Circulation 1998;98:I320.
100. Gelband CH, Reaves PY, Evans J et al. Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension. Hypertension 1999;33:360-365.
101. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther 1998;9:1429-1438.
102. Phillips MI. Is gene therapy for hypertension possible? Hypertension 1999;33:8-13.
103. Janssens SP, Bloch KD, Nong Z et al. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 1996;98:317-324.
104. Budts W, Nong Z, Vermeersch P et al. Inhibition of chronic hypoxic pulmonary hypertension by nitric oxide synthase aerosol gene transfer [abstract]. Eur Heart J 1998;19(Suppl):586.
105. Morishita R, Nakagami H, Taniyama Y et al. Oligonucleotidebased gene therapy for cardiovascular disease. Clin Chem Lab Med 1998;36:529-534.
106. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-1028.
107. Fallaux FJ, Bout A, van derVelde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-1917.
108. Qian H, Wang Q, Channon KM et al. An adenovirus with E1 and E4 deletions shows improved performance for vascular gene therapy [abstract]. Circulation 1998;98:I669.
109. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther 1997;4:393-400.
110. Ji L, Bouvet M, Price RE, Roth JA, Fang B. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Ther 1999;6:393-402.
111. Schiedner G, Morral N, Parks RJ et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18:180-183.
112. Lynch CM, Hara PS, Leonard JC et al. Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997;80:497-505.
113. Rolling F, Nong Z, Pisvin S, Collen D. Adeno-associated virusmediated gene transfer into rat carotid arteries. Gene Ther 1997;4:757-761.
114. Zolotukhin S, Byrne BJ, Mason E et al. Recombinant adenoassociated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
115. Mohuczy D, Gelband CH, Phillips MI. Antisense inhibition of AT1 receptor in vascular smooth muscle cells using adeno-associated virus-based vector. Hypertension 1999;33:354-359.
116. Fan L, Drew J, Dunckley MG, Owen JS, Dickson G. Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors. Gene Ther 1998;5:1434-1440.
117. Zhu NL, Wu L, Liu PX et al. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997;96:628-635.
118. Klimatcheva E, Rosenblatt JD, Planelles V. Lentiviral vectors and gene therapy. Front Biosci 1999;1:D481-96.
119. Pakkanen TM, Laitinen M, Hippelainen M et al. Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase-ganciclovir treatment. Gene Ther 1999;6:34-41.
120. Porter T, Hiser W, Li S et al. Non-invasive prevention of lumen area narrowing following coronary balloon injury with intravenous antisense to the c-myc protooncogene bound to perfluorocarbon microbubbles [abstract]. Circulation 1998;98:503.
121. Franz WM, Rothmann T, Frey N, Katus HA. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res 1997;35:560-566.
122. Nguyen T, Mano T, Willis KN. Targeted suppression of smooth muscle cell proliferation using adenovirus mediated delivery of an Rb-E2F hybrid gene expressed from the smooth muscle actin promotor [abstract]. Circulation 1998;98:I670.
123. Masaki H, Kurihara T, Yamaki A et al. Cardiac-specific over-expression of angiotensin II AT2 receptor causes attenuated response to ATI receptor-mediated pressor and chronotropic effects. J Clin Invest 1998;101:527-535.
124. Prentice H, Bishopric NH, Hicks MN et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc Res 1997;35:567-574.
125. Hall FL, Gordon EM, Wu L et al. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther 1997;8:2183-2192.